SEHK:2696Biotechs
Assessing Shanghai Henlius Biotech’s Valuation As HLX11 And HLX22 Breast Cancer Programs Gain Momentum
Why HLX11 and HLX22 are in focus for Shanghai Henlius Biotech (SEHK:2696)
Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after two breast cancer program updates, including a positive CHMP opinion in Europe for its Perjeta biosimilar HLX11 and progress in its HER2 combination study HLX22 plus HLX87 in China.
See our latest analysis for Shanghai Henlius Biotech.
Even after a 4.42% one day share price decline to HK$65.95, Shanghai Henlius Biotech’s 12.54% year to date share...